Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer

doi:10.3969/j.issn.1006-7795.2023.05.026

Abstract

Abstract: Triple negative breast cancer (TNBC) is associated with high invasiveness, high metastasis，high risk of recurrence and metastasis. Currently, there is still a lack of effective molecular therapeutic targets, and the median survival time for patients with advanced disease is only 1 year, which is the worst prognosis for a subtype of breast cancer. It has been identified that there are a variety of tumor-associated immune cells and stromal cells in the tumor microenvironment（TME）, which play a key role in the development, invasion and metastasis of TNBC, now an increasing numbers of studies are focusing on the value of immunotherapy in TNBC. TME hosts many potential targets for immunotherapy, and the thorough exploration of TME may provide new perspectives for immunotherapy in TNBC. This study provides a comprehensive review of the latest advances in understanding the components of the TME in TNBC，and their associated targeted therapeutic strategies.

Key words: triple negative breast cancer, tumor microenvironment, immunotherapy, , tumor-infiltrating lymphocytes, immune checkpoint

CLC Number:

R737.9

Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer[J]. Journal of Capital Medical University, 2023, 44(5): 882-888.

References

［1］Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022［J］. CA Cancer J Clin, 2022, 72(1): 7-33.
［2］Sakach E, O'Regan R, Meisel J, et al. Molecular classification of triple negative breast cancer and the emergence of targeted therapies［J］. Clin Breast Cancer, 2021, 21(6): 509-520.
［3］Nelson M A, Ngamcherdtrakul W, Luoh S W, et al. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer［J］. Cancer Metastasis Rev, 2021, 40(2): 519-536.
［4］Denkert C, Von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy［J］. Lancet Oncol, 2018, 19(1): 40-50.
［5］Luen S J, Salgado R, Dieci M V, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy［J］. Ann Oncol, 2019, 30(2): 236-242.
［6］丁耘峰, 黄惠莲, 徐炜, 等. 三阴性乳腺癌组织中PD-1/PD-L1轴表达与TILs关系及临床病意义［J］. 临床肿瘤学杂志, 2021, 26(2): 140-145.
［7］Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers［J］. J Clin Oncol, 2019, 37(7): 559-569.
［8］Dieci M V, Tsvetkova V, Griguolo G, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: analysis of 244 stage Ⅰ-Ⅲ patients treated with standard therapy［J］. Eur J Cancer, 2020, 136: 7-15.
［9］钟恋君, 王进京, 郑洪. 三阴型乳腺癌间质肿瘤浸润淋巴细胞CD4、CD8、Foxp3和PD-L1表达的临床病理意义［J］. 临床与实验病理学杂志, 2022, 38(3): 278-283, 288.
［10］Goda N, Nakashima C, Nagamine I, et al. The effect of intratumoral interrelation among FOXP3+ regulatory T cells on treatment response and survival in triple-negative breast cancer［J］. Cancers (Basel), 2022, 14(9): 2138.
［11］Yao S, Zhu Y W, Chen L P. Advances in targeting cell surface signalling molecules for immune modulation［J］. Nat Rev Drug Discov, 2013, 12(2): 130-146.
［12］Quintana Á, Peg V, Prat A, et al. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer［J］. Eur J Cancer, 2021, 148: 134-145.
［13］Liu J N, Kong X S, Huang T, et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study［J］. Front Immunol, 2020, 11: 2048.
［14］Vardas V, Tolios A, Christopoulou A, et al. Immune checkpoint and EMT-related molecules in circulating tumor cells (CTCs) from triple negative breast cancer patients and their clinical impact［J］. Cancers (Basel), 2023, 15(7): 1974.
［15］Quezada S A, Peggs K S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer［J］. Br J Cancer, 2013, 108(8): 1560-1565.
［16］Hoda R S, Brogi E, Dos Anjos C H, et al. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma［J］. Mod Pathol, 2020, 33(11): 2221-2232.
［17］Sun X J, Zhai J, Sun B H, et al. Effector memory cytotoxic CD3⁺/CD8⁺/CD45RO⁺ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer［J］. Mod Pathol, 2022, 35(5): 601-608.
［18］刘鲁宁, 陈雪梅, 马恩奇, 等. 人CD137抗体促进NK细胞对乳腺癌细胞特异性杀伤作用的体外研究［J］. 中华细胞与干细胞杂志: 电子版, 2020, 10(6): 346-353.
［19］Jin H, Choi H, Kim E S, et al. Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase-type plasminogen activator［J］. Oncol Rep, 2021, 45(1): 299-308.
［20］Milling L E, Garafola D, Agarwal Y, et al. Neoadjuvant sting activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation［J］. Cancer Immunol Res, 2022, 10(1): 26-39.
［21］Ding S N, Qiao N, Zhu Q C, et al. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer［J］. Cancer Commun (Lond), 2023, 43(6): 661-684.
［22］Yang M, Ma B, Shao H S, et al. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells［J］. BMC Cancer, 2016, 16: 419.
［23］Noy R, Pollard J W. Tumor-associated macrophages: from mechanisms to therapy［J］. Immunity, 2014, 41(1): 49-61.
［24］Steenbrugge J, Breyne K, Demeyere K, et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer［J］. J Exp Clin Cancer Res, 2018, 37(1): 191.
［25］Yuan Z Y, Luo R Z, Peng R J, et al. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis［J］. Onco Targets Ther, 2014, 7: 1475-1480.
［26］Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast［J］. Virchows Arch, 2020, 477(6): 767-775.
［27］Bao X W, Shi R, Zhao T Y, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC［J］. Cancer Immunol Immunother, 2021, 70(1): 189-202.
［28］Fridlender Z G, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN［J］. Cancer Cell, 2009, 16(3): 183-194.
［29］Wei B J, Yao M Y, Xing C Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis［J］. Onco Targets Ther, 2016, 9: 5567-5575.
［30］Gao S M, Tang W J, Zuo B L, et al. The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy［J］. Front Oncol, 2022, 12: 1065606.
［31］Schott A F, Goldstein L J, Cristofanilli M, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer［J］. Clin Cancer Res, 2017, 23(18): 5358-5365.
［32］Li K D, Liu T, Chen J, et al. Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis［J］. J Biol Chem, 2020, 295(40): 13737-13752.
［33］Liubomirski Y, Lerrer S, Meshel T, et al. Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast cancer［J］. Front Immunol, 2019, 10: 804.
［34］Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer［J］. Cancer Cell, 2018, 33(3): 463-479.e10.
［35］Alcaraz L B, Mallavialle A, Mollevi C, et al. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity［J］. Int J Cancer, 2023, 152(6): 1243-1258.
［36］Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion［J］. Cancer Res, 2011, 71(7): 2455-2465.
［37］Zhao C R, Wu M, Zeng N, et al. Cancer-associated adipocytes: emerging supporters in breast cancer［J］. J Exp Clin Cancer Res, 2020, 39(1): 156.
［38］Zhang C Y, Yue C Y, Herrmann A, et al. STAT3 Activation-induced fatty acid oxidation in CD8⁺ T effector cells is critical for obesity-promoted breast tumor growth［J］. Cell Metab, 2020, 31(1): 148-161.e5.
［39］Liu Q, Dong H T, Zhao T T, et al. Cancer-associated adipocytes release FUCA2 to promote aggressiveness in TNBC［J］. Endocr Relat Cancer, 2022, 29(3): 139-149.
［40］Alshetaiwi H, Pervolarakis N, McIntyre L L, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics［J］. Sci Immunol, 2020, 5(44): eaay6017.
［41］Kumar V, Donthireddy L, Marvel D, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors［J］. Cancer Cell, 2017, 32(5): 654-668.e5.
［42］Vito A, Salem O, El-Sayes N, et al. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells［J］. Commun Biol, 2021, 4(1): 859.
［43］Pickup M W, Mouw J K, Weaver V M. The extracellular matrix modulates the hallmarks of cancer［J］. EMBO Rep, 2014, 15(12): 1243-1253.
［44］Hayashi M, Yamamoto Y, Ibusuki M, et al. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer［J］. Ann Surg Oncol, 2012, 19(9): 3042-3049.
［45］Turunen S P, Tatti-Bugaeva O, Lehti K. Membrane-type matrix metalloproteases as diverse effectors of cancer progression［J］. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A): 1974-1988.

[1]	Guo Yan, Xia Enlan, Xiao Yu, Huang Xiaowu. Multivariate analysis of pregnancy outcomes after transcervical resection of polyp in infertility patients [J]. Journal of Capital Medical University, 2025, 46(4): 724-728.
[2]	Jiang Haiping, Yin Shuo, Li Shenglan, Li Wenbin. The progress in the role and application of neutrophils in glioma [J]. Journal of Capital Medical University, 2025, 46(3): 448-454.
[3]	Huang Min. Resting energy expenditure of overweight and obese people and its correlation with body compositions [J]. Journal of Capital Medical University, 2025, 46(3): 581-585.
[4]	Zi Xiaohui, Xia Xue, Li jing, Zhang Xiaoli, Zhou Quan, Wang Anxin, Wang Yilong. Advances in the application of antiplatelet therapy in intravenous thrombolysis for acute ischemic stroke patients [J]. Journal of Capital Medical University, 2025, 46(2): 234-242.
[5]	Wang Yinping, Meng Cancan, Wu Wenjuan, Yang Zhitang. The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times [J]. Journal of Capital Medical University, 2025, 46(1): 34-40.
[6]	Wei Xingmei, Xue Shujin, Gao Zhencheng, Li Yongxin. The application of artificial intelligence in cochlear implantation [J]. Journal of Capital Medical University, 2024, 45(6): 931-937.
[7]	Zhou Yan, Wu Wei. Ethenic Chinese scientist Chen Zhijian discovers the cGAS-STING signaling pathway that senses DNA for immune surveillance——the 2024 Lasker Basic Medical Research Awards [J]. Journal of Capital Medical University, 2024, 45(5): 923-927.
[8]	Li Tiezheng, Xu Kaikai, Deng Yuqing, Wang Peihao, Qin Qi, Guo Kangshun, Wang Bingren, Chang Dong, Cui Yong. Analysis of the efficacy and safety of PD-1 inhibitors combined with chemotherapy in neoadjuvant treatment of locally advanced non-small cell lung cancer [J]. Journal of Capital Medical University, 2024, 45(4): 636-641.
[9]	Wu Zhaozhen, Zheng Hua, Sheng Shuyan, Zhang Quan, Zhang Hui, Li Jie, Lyu Jialin, Qian Zhe, Wang Shouzheng, Li Xi , Hu Ying. Observation on the preliminary efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer [J]. Journal of Capital Medical University, 2024, 45(4): 642-648.
[10]	Wang Jusi, Song Weian, Di Shouyin, Liu Junqiang, Fan Boshi, Zhou Shaohua, Yue Caiying, Zhao Jiahua, Chen Siyu, Gong Taiqian. Efficacy of neoadjuvant chemotherapy combined with immunotherapy in the treatment of stage Ⅲ non-small cell lung cancer [J]. Journal of Capital Medical University, 2024, 45(4): 660-665.
[11]	Hao Zhuohong, Yun Duo, Zhang Ying, Li Huihui, Lin Haishan, Cui Yong, Zhao Lei. Advances in research of perioperative immunotherapy for non-small cell lung cancer—advances in neoadjuvant immunotherapy [J]. Journal of Capital Medical University, 2024, 45(4): 666-677.
[12]	Zhang Daqian, Zhang Xiaoxin, Ye Zichen, Xie Zhilan, Yang Jichun, Jiang Yu. Diagnostic value of artificial intelligence assisted diagnostic system for acute leukemia: a Meta-analysis [J]. Journal of Capital Medical University, 2024, 45(4): 693-700.
[13]	Huang Xiaohui, Wang Xinwei, Wu Jie. Predictive value of neutrophil to lymphocyte ratio and platelet count combined with D-dimer in the prognosis of children with severe pneumonia complicated with sepsis [J]. Journal of Capital Medical University, 2024, 45(4): 721-726.
[14]	Liu Chang, Xin Zhong, Yang Jinkui. Relationship between diet quality scores and all-cause mortality in diabetic patients of different genders [J]. Journal of Capital Medical University, 2024, 45(3): 406-412.
[15]	Zheng Ming , Wu Jianyou , Sima Yutong, Wang Xiangdong, Zhang Luo, . Comparison of clinical characteristics between odontogenic sinusitis patients with and without sinusitis symptoms [J]. Journal of Capital Medical University, 2024, 45(2): 239-245.